Literature DB >> 8134290

Enhanced expression of neurotensin/neuromedin N mRNA and products of NT/NMN precursor processing in neonatal rats.

K Muraki1, S P Mitra, P R Dobner, R E Carraway.   

Abstract

Intestinal levels of immunoreactive neurotensin (iNT) and neuromedin N (iNMN), as well as mRNA for the NT/NMN precursor, were elevated during the suckling period in rats. While transient expression of NT/NMN was observed at 1-5 days of age in the proximal small intestine and colon, NT/NMN levels in the ileum increased to peak at 10-20 days of age and then decreased to adult levels. The levels of these peptides were not elevated in the central nervous system and pituitary over this time period. Chromatographic analyses of jejunoileal extracts indicated that large molecular forms of iNT and iNMN were present, constituting approximately 1.3% of total iNT and approximately 56% of total iNMN, respectively. Treatment of the large forms with pepsin, which is known to generate the fully immunoreactive peptides, NT(3-13), NT(4-13), and NMN, increased immunoreactivity tenfold (iNT) and 1.2-fold (iNMN). Thus, large forms actually constituted approximately 13% (iNT) and approximately 60% (iNMN). Based upon its physicochemical properties, large molecular iNMN was tentatively identified as a 125 residue peptide with NMN at its C-terminus [i.e., rat prepro-NT/NMN(23-147)]. The properties of large molecular iNT were most similar to those predicted for the entire precursor [i.e., rat prepro-NT/NMN(23-169)]. These results indicate a) that enhanced expression of NT/NMN occurs in a tissue-specific manner in rats during the suckling period; b) that the pattern of precursor processing in intestine yields primarily NT and a large molecular form of NMN.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8134290     DOI: 10.1016/0196-9781(93)90161-9

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  5 in total

1.  Characterization of promoter elements regulating the expression of the human neurotensin/neuromedin N gene.

Authors:  Xiaofu Wang; Pat Gulhati; Jing Li; Paul R Dobner; Heidi Weiss; Courtney M Townsend; B Mark Evers
Journal:  J Biol Chem       Date:  2010-10-28       Impact factor: 5.157

2.  Fetal and neoplastic expression of the neurotensin gene in the human colon.

Authors:  B M Evers; Z Zhou; V Dohlen; S Rajaraman; J C Thompson; C M Townsend
Journal:  Ann Surg       Date:  1996-05       Impact factor: 12.969

3.  Neurotensin is a proinflammatory neuropeptide in colonic inflammation.

Authors:  I Castagliuolo; C C Wang; L Valenick; A Pasha; S Nikulasson; R E Carraway; C Pothoulakis
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

4.  The neurotensin gene is a downstream target for Ras activation.

Authors:  B M Evers; Z Zhou; P Celano; J Li
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

5.  Characterization of promoter elements required for cell-specific expression of the neurotensin/neuromedin N gene in a human endocrine cell line.

Authors:  B M Evers; X Wang; Z Zhou; C M Townsend; G P McNeil; P R Dobner
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.